After Benchmark Co. and J.P. Morgan gave Invitae (NYSE: NVTA) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Kevin DeGeeter reiterated a Buy rating on Invitae today. The company’s shares opened today at $24.75, close to its 52-week high of $25.33.
According to TipRanks.com, DeGeeter is a 4-star analyst with an average return of 15.3% and a 53.8% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences Inc, Molecular Templates Inc, and Neon Therapeutics Inc.
Currently, the analyst consensus on Invitae is a Strong Buy with an average price target of $22.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.33 and a one-year low of $4.35. Currently, Invitae has an average volume of 1.7M.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVTA in relation to earlier this year. Earlier this month, Robert Nussbaum, the CMO of NVTA bought 10,000 shares for a total of $99,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.
